{"id":"https://openalex.org/W7223474701","doi":"https://doi.org/10.1002/cpdd.70115","title":"Safety, Tolerability, and Pharmacokinetics of EGT710, a Novel Coronavirus M pro Inhibitor, in Healthy Adults: A Randomized, Single\u2010 and Multiple\u2010Dose Study","display_name":"Safety, Tolerability, and Pharmacokinetics of EGT710, a Novel Coronavirus M pro Inhibitor, in Healthy Adults: A Randomized, Single\u2010 and Multiple\u2010Dose Study","publication_year":2026,"publication_date":"2026-10-01","ids":{"openalex":"https://openalex.org/W7223474701","doi":"https://doi.org/10.1002/cpdd.70115","pmid":"https://pubmed.ncbi.nlm.nih.gov/42925259","pmcid":"https://www.ncbi.nlm.nih.gov/pmc/articles/13695357"},"language":"en","primary_location":{"id":"doi:10.1002/cpdd.70115","doi":"https://doi.org/10.1002/cpdd.70115","is_oa":true,"landing_page_url":"https://doi.org/10.1002/cpdd.70115","pdf_url":"https://onlinelibrary.wiley.com/doi/pdfdirect/10.1002/cpdd.70115","source":{"id":"https://openalex.org/S2764863641","display_name":"Clinical Pharmacology in Drug Development","issn_l":"2160-763X","issn":["2160-763X","2160-7648"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["cwts-core","dongbi-b","jufo-1","ki-jl-1","medline","norway-1","poland-40","russia-white-list-2"],"host_organization":"https://openalex.org/P4310320595","host_organization_name":"Wiley","host_organization_lineage":["https://openalex.org/P4310320595"],"host_organization_lineage_names":["Wiley"],"type":"journal"},"license":"cc-by","license_id":"https://openalex.org/licenses/cc-by","version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Clinical Pharmacology in Drug Development","raw_type":"journal-article"},"volume":null,"type":"article","is_traditional":true,"indexed_in":["crossref","pubmed"],"open_access":{"is_oa":true,"oa_status":"hybrid","oa_url":"https://onlinelibrary.wiley.com/doi/pdfdirect/10.1002/cpdd.70115","any_repository_has_fulltext":true},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5081922548","display_name":"Jart A. F. Oosterhaven","orcid":"https://orcid.org/0000-0001-7214-7528","observed_orcids":["https://orcid.org/0000-0001-7214-7528"]},"institutions":[{"id":"https://openalex.org/I4405266959","display_name":"ICON PLC (Ireland)","ror":"https://ror.org/00gmhs392","country_code":"IE","type":"company","lineage":["https://openalex.org/I4405266959"]}],"countries":["IE"],"is_corresponding":false,"raw_author_name":"Jart A. F. Oosterhaven","raw_affiliation_strings":["ICON Plc  Groningen The Netherlands"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"ICON Plc  Groningen The Netherlands","institution_ids":["https://openalex.org/I4405266959"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5093089146","display_name":"Jonathan Trolander","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210117619","display_name":"Novartis (United States)","ror":"https://ror.org/028fhxy95","country_code":"US","type":"company","lineage":["https://openalex.org/I1283582996","https://openalex.org/I4210117619"]}],"countries":["US"],"is_corresponding":true,"raw_author_name":"Jonathan Trolander","raw_affiliation_strings":["CA CSI CVM, Biomedical Research, Novartis  Cambridge MA USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"CA CSI CVM, Biomedical Research, Novartis  Cambridge MA USA","institution_ids":["https://openalex.org/I4210117619"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5056147363","display_name":"Lidiya Bebrevska","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I1283582996","display_name":"Novartis (Switzerland)","ror":"https://ror.org/02f9zrr09","country_code":"CH","type":"company","lineage":["https://openalex.org/I1283582996"]}],"countries":["CH"],"is_corresponding":false,"raw_author_name":"Lidiya Bebrevska","raw_affiliation_strings":["Global Health, Research & Development, Pharmacokinetics, Novartis Pharma AG  Basel Switzerland"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Global Health, Research & Development, Pharmacokinetics, Novartis Pharma AG  Basel Switzerland","institution_ids":["https://openalex.org/I1283582996"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5032036761","display_name":"Hilmar Schiller","orcid":"https://orcid.org/0000-0002-1026-3985","observed_orcids":["https://orcid.org/0000-0002-1026-3985"]},"institutions":[{"id":"https://openalex.org/I1283582996","display_name":"Novartis (Switzerland)","ror":"https://ror.org/02f9zrr09","country_code":"CH","type":"company","lineage":["https://openalex.org/I1283582996"]}],"countries":["CH"],"is_corresponding":false,"raw_author_name":"Hilmar Schiller","raw_affiliation_strings":["Global Health, Research & Development, Pharmacokinetics, Novartis Pharma AG  Basel Switzerland"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Global Health, Research & Development, Pharmacokinetics, Novartis Pharma AG  Basel Switzerland","institution_ids":["https://openalex.org/I1283582996"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5013237196","display_name":"Begum Alaybeyoglu","orcid":"https://orcid.org/0000-0001-6785-3719","observed_orcids":["https://orcid.org/0000-0001-6785-3719"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Begum Alaybeyoglu","raw_affiliation_strings":["Early Development Analytics, Development, Novartis Pharmaceuticals Corporation  Cambridge MA USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Early Development Analytics, Development, Novartis Pharmaceuticals Corporation  Cambridge MA USA","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5089810766","display_name":"Suzanne Gaudet","orcid":"https://orcid.org/0000-0002-5701-2825","observed_orcids":["https://orcid.org/0000-0002-5701-2825"]},"institutions":[{"id":"https://openalex.org/I4210117619","display_name":"Novartis (United States)","ror":"https://ror.org/028fhxy95","country_code":"US","type":"company","lineage":["https://openalex.org/I1283582996","https://openalex.org/I4210117619"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Suzanne Gaudet","raw_affiliation_strings":["CA CSI CVM, Biomedical Research, Novartis  Cambridge MA USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"CA CSI CVM, Biomedical Research, Novartis  Cambridge MA USA","institution_ids":["https://openalex.org/I4210117619"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5076928540","display_name":"Allison Claas","orcid":"https://orcid.org/0000-0002-4150-6214","observed_orcids":["https://orcid.org/0000-0002-4150-6214"]},"institutions":[{"id":"https://openalex.org/I4210117619","display_name":"Novartis (United States)","ror":"https://ror.org/028fhxy95","country_code":"US","type":"company","lineage":["https://openalex.org/I1283582996","https://openalex.org/I4210117619"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Allison Claas","raw_affiliation_strings":["CA CSI CVM, Biomedical Research, Novartis  Cambridge MA USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"CA CSI CVM, Biomedical Research, Novartis  Cambridge MA USA","institution_ids":["https://openalex.org/I4210117619"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5007415732","display_name":"Kamal Kumar Balavenkatraman","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I1283582996","display_name":"Novartis (Switzerland)","ror":"https://ror.org/02f9zrr09","country_code":"CH","type":"company","lineage":["https://openalex.org/I1283582996"]}],"countries":["CH"],"is_corresponding":false,"raw_author_name":"Kamal Kumar Balavenkatraman","raw_affiliation_strings":["Preclinical Safety Biomedical Research, Novartis Pharma AG  Basel Switzerland"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Preclinical Safety Biomedical Research, Novartis Pharma AG  Basel Switzerland","institution_ids":["https://openalex.org/I1283582996"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5126663313","display_name":"Renee Bergeron","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210117619","display_name":"Novartis (United States)","ror":"https://ror.org/028fhxy95","country_code":"US","type":"company","lineage":["https://openalex.org/I1283582996","https://openalex.org/I4210117619"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Renee Bergeron","raw_affiliation_strings":["Preclinical Safety Novartis Pharmaceuticals Corporation  East Hanover NJ USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Preclinical Safety Novartis Pharmaceuticals Corporation  East Hanover NJ USA","institution_ids":["https://openalex.org/I4210117619"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5005522087","display_name":"Fernanda V. Dur\u00e3es","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I1283582996","display_name":"Novartis (Switzerland)","ror":"https://ror.org/02f9zrr09","country_code":"CH","type":"company","lineage":["https://openalex.org/I1283582996"]}],"countries":["CH"],"is_corresponding":false,"raw_author_name":"Fernanda V. Duraes","raw_affiliation_strings":["CS&I Immunology, Biomedical Research Novartis Pharma AG  Basel Switzerland"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"CS&I Immunology, Biomedical Research Novartis Pharma AG  Basel Switzerland","institution_ids":["https://openalex.org/I1283582996"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5013346333","display_name":"Fr\u00e9d\u00e9rique Chaperon","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I1283582996","display_name":"Novartis (Switzerland)","ror":"https://ror.org/02f9zrr09","country_code":"CH","type":"company","lineage":["https://openalex.org/I1283582996"]}],"countries":["CH"],"is_corresponding":false,"raw_author_name":"Frederique Chaperon","raw_affiliation_strings":["CS&I Immunology, Biomedical Research Novartis Pharma AG  Basel Switzerland"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"CS&I Immunology, Biomedical Research Novartis Pharma AG  Basel Switzerland","institution_ids":["https://openalex.org/I1283582996"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5126668488","display_name":"Swati Ghanshani","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210090302","display_name":"Novartis (India)","ror":"https://ror.org/00dhvr506","country_code":"IN","type":"company","lineage":["https://openalex.org/I1283582996","https://openalex.org/I4210090302"]}],"countries":["IN"],"is_corresponding":false,"raw_author_name":"Swati Ghanshani","raw_affiliation_strings":["Biostatistics & Pharmacometrics Novartis Healthcare Private Limited  Mumbai India"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Biostatistics & Pharmacometrics Novartis Healthcare Private Limited  Mumbai India","institution_ids":["https://openalex.org/I4210090302"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5053700308","display_name":"Elisabete Goncalves","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I1283582996","display_name":"Novartis (Switzerland)","ror":"https://ror.org/02f9zrr09","country_code":"CH","type":"company","lineage":["https://openalex.org/I1283582996"]}],"countries":["CH"],"is_corresponding":false,"raw_author_name":"Elisabete Goncalves","raw_affiliation_strings":["Global Health, Research & Development, Pharmacokinetics, Novartis Pharma AG  Basel Switzerland"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Global Health, Research & Development, Pharmacokinetics, Novartis Pharma AG  Basel Switzerland","institution_ids":["https://openalex.org/I1283582996"]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5103136520","display_name":"Steven J. Kovacs","orcid":"https://orcid.org/0000-0003-4001-7053","observed_orcids":["https://orcid.org/0000-0003-4001-7053"]},"institutions":[{"id":"https://openalex.org/I4210117619","display_name":"Novartis (United States)","ror":"https://ror.org/028fhxy95","country_code":"US","type":"company","lineage":["https://openalex.org/I1283582996","https://openalex.org/I4210117619"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Steven J. Kovacs","raw_affiliation_strings":["Translational Medicine Novartis Pharmaceuticals Corporation  East Hanover NJ USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Translational Medicine Novartis Pharmaceuticals Corporation  East Hanover NJ USA","institution_ids":["https://openalex.org/I4210117619"]}]}],"institutions":[],"countries_distinct_count":4,"institutions_distinct_count":4,"corresponding_author_ids":["https://openalex.org/A5093089146"],"corresponding_institution_ids":["https://openalex.org/I4210117619"],"apc_list":{"value":3800,"currency":"USD","value_usd":3800},"apc_paid":{"value":3800,"currency":"USD","value_usd":3800},"fwci":0.0,"has_fulltext":true,"cited_by_count":0,"citation_normalized_percentile":{"value":0.81861775,"is_in_top_1_percent":false,"is_in_top_10_percent":false},"cited_by_percentile_year":null,"biblio":{"volume":"15","issue":"10","first_page":null,"last_page":null},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T10118","display_name":"SARS-CoV-2 and COVID-19 Research","score":0.8544999957084656,"subfield":{"id":"https://openalex.org/subfields/2725","display_name":"Infectious Diseases"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T10118","display_name":"SARS-CoV-2 and COVID-19 Research","score":0.8544999957084656,"subfield":{"id":"https://openalex.org/subfields/2725","display_name":"Infectious Diseases"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10041","display_name":"COVID-19 Clinical Research Studies","score":0.0957999974489212,"subfield":{"id":"https://openalex.org/subfields/2725","display_name":"Infectious Diseases"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10375","display_name":"Pharmacogenetics and Drug Metabolism","score":0.018200000748038292,"subfield":{"id":"https://openalex.org/subfields/3004","display_name":"Pharmacology"},"field":{"id":"https://openalex.org/fields/30","display_name":"Pharmacology, Toxicology and Pharmaceutics"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/sars-cov-2","display_name":"SARS-CoV-2","score":0.8199999928474426},{"id":"https://openalex.org/keywords/covid-19-antiviral-therapy","display_name":"COVID-19 antiviral therapy","score":0.9079999923706055},{"id":"https://openalex.org/keywords/pharmacokinetics","display_name":"pharmacokinetics","score":0.843999981880188},{"id":"https://openalex.org/keywords/safety-and-tolerability","display_name":"safety and tolerability","score":0.8330000042915344},{"id":"https://openalex.org/keywords/bioavailability","display_name":"bioavailability","score":0.8389999866485596},{"id":"https://openalex.org/keywords/food-effect","display_name":"food effect","score":0.7400000095367432},{"id":"https://openalex.org/keywords/cyp3a4-induction","display_name":"CYP3A4 induction","score":0.8920000195503235},{"id":"https://openalex.org/keywords/first-in-human-study","display_name":"first-in-human study","score":0.5339999794960022}],"concepts":[{"id":"https://openalex.org/C112705442","wikidata":"https://www.wikidata.org/wiki/Q323936","display_name":"Pharmacokinetics","level":2,"score":0.9176999926567078},{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.8476999998092651},{"id":"https://openalex.org/C197934379","wikidata":"https://www.wikidata.org/wiki/Q2047938","display_name":"Adverse effect","level":2,"score":0.6851999759674072},{"id":"https://openalex.org/C2777648638","wikidata":"https://www.wikidata.org/wiki/Q57751738","display_name":"Coronavirus","level":5,"score":0.6328999996185303},{"id":"https://openalex.org/C181389837","wikidata":"https://www.wikidata.org/wiki/Q461809","display_name":"Bioavailability","level":2,"score":0.6162999868392944},{"id":"https://openalex.org/C98274493","wikidata":"https://www.wikidata.org/wiki/Q128406","display_name":"Pharmacology","level":1,"score":0.6015999913215637},{"id":"https://openalex.org/C2778778583","wikidata":"https://www.wikidata.org/wiki/Q147768","display_name":"Capsule","level":2,"score":0.49079999327659607},{"id":"https://openalex.org/C3008058167","wikidata":"https://www.wikidata.org/wiki/Q84263196","display_name":"Coronavirus disease 2019 (COVID-19)","level":4,"score":0.4828000068664551},{"id":"https://openalex.org/C2781143361","wikidata":"https://www.wikidata.org/wiki/Q55761529","display_name":"Protease inhibitor (pharmacology)","level":5,"score":0.3982999920845032},{"id":"https://openalex.org/C109650736","wikidata":"https://www.wikidata.org/wiki/Q424440","display_name":"CYP3A4","level":4,"score":0.37369999289512634},{"id":"https://openalex.org/C3007834351","wikidata":"https://www.wikidata.org/wiki/Q82069695","display_name":"Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)","level":5,"score":0.3686000108718872},{"id":"https://openalex.org/C2777056448","wikidata":"https://www.wikidata.org/wiki/Q285166","display_name":"Oral administration","level":2,"score":0.33469998836517334},{"id":"https://openalex.org/C76318530","wikidata":"https://www.wikidata.org/wiki/Q16833590","display_name":"Area under the curve","level":2,"score":0.329800009727478},{"id":"https://openalex.org/C159047783","wikidata":"https://www.wikidata.org/wiki/Q7215","display_name":"Virology","level":1,"score":0.3181999921798706},{"id":"https://openalex.org/C2909376813","wikidata":"https://www.wikidata.org/wiki/Q57751738","display_name":"Coronavirus Infections","level":5,"score":0.30820000171661377},{"id":"https://openalex.org/C3006700255","wikidata":"https://www.wikidata.org/wiki/Q81068910","display_name":"2019-20 coronavirus outbreak","level":3,"score":0.302700012922287},{"id":"https://openalex.org/C2777182164","wikidata":"https://www.wikidata.org/wiki/Q422585","display_name":"Lopinavir","level":5,"score":0.30239999294281006},{"id":"https://openalex.org/C90924648","wikidata":"https://www.wikidata.org/wiki/Q120569","display_name":"Gastroenterology","level":1,"score":0.287200003862381},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.2581000030040741},{"id":"https://openalex.org/C2776714187","wikidata":"https://www.wikidata.org/wiki/Q212410","display_name":"Protease","level":3,"score":0.25119999051094055}],"mesh":[{"descriptor_ui":"D000086402","descriptor_name":"SARS-CoV-2","qualifier_ui":"Q000187","qualifier_name":"drug effects","is_major_topic":true},{"descriptor_ui":"D000086782","descriptor_name":"Coronavirus 3C Proteases","qualifier_ui":"Q000037","qualifier_name":"antagonists & inhibitors","is_major_topic":true},{"descriptor_ui":"D000093485","descriptor_name":"COVID-19 Drug Treatment","qualifier_ui":null,"qualifier_name":null,"is_major_topic":true},{"descriptor_ui":"D000284","descriptor_name":"Administration, Oral","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D000328","descriptor_name":"Adult","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D000998","descriptor_name":"Antiviral Agents","qualifier_ui":"Q000008","qualifier_name":"administration & dosage","is_major_topic":true},{"descriptor_ui":"D000998","descriptor_name":"Antiviral Agents","qualifier_ui":"Q000009","qualifier_name":"adverse effects","is_major_topic":true},{"descriptor_ui":"D000998","descriptor_name":"Antiviral Agents","qualifier_ui":"Q000493","qualifier_name":"pharmacokinetics","is_major_topic":true},{"descriptor_ui":"D001682","descriptor_name":"Biological Availability","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D004305","descriptor_name":"Dose-Response Relationship, Drug","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D004311","descriptor_name":"Double-Blind Method","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D005260","descriptor_name":"Female","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D006801","descriptor_name":"Humans","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D008297","descriptor_name":"Male","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D008875","descriptor_name":"Middle Aged","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D009426","descriptor_name":"Netherlands","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D018565","descriptor_name":"Food-Drug Interactions","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D018592","descriptor_name":"Cross-Over Studies","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D019540","descriptor_name":"Area Under Curve","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D055815","descriptor_name":"Young Adult","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D064368","descriptor_name":"Healthy Volunteers","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false}],"locations_count":3,"locations":[{"id":"doi:10.1002/cpdd.70115","doi":"https://doi.org/10.1002/cpdd.70115","is_oa":true,"landing_page_url":"https://doi.org/10.1002/cpdd.70115","pdf_url":"https://onlinelibrary.wiley.com/doi/pdfdirect/10.1002/cpdd.70115","source":{"id":"https://openalex.org/S2764863641","display_name":"Clinical Pharmacology in Drug Development","issn_l":"2160-763X","issn":["2160-763X","2160-7648"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["cwts-core","dongbi-b","jufo-1","ki-jl-1","medline","norway-1","poland-40","russia-white-list-2"],"host_organization":"https://openalex.org/P4310320595","host_organization_name":"Wiley","host_organization_lineage":["https://openalex.org/P4310320595"],"host_organization_lineage_names":["Wiley"],"type":"journal"},"license":"cc-by","license_id":"https://openalex.org/licenses/cc-by","version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Clinical Pharmacology in Drug Development","raw_type":"journal-article"},{"id":"pmh:oai:pubmedcentral.nih.gov:13695357","doi":null,"is_oa":true,"landing_page_url":"https://pmc.ncbi.nlm.nih.gov/articles/PMC13695357/","pdf_url":"https://pmc.ncbi.nlm.nih.gov/articles/PMC13695357/pdf/CPDD-15-0.pdf","source":{"id":"https://openalex.org/S2764455111","display_name":"PubMed Central","issn_l":null,"issn":null,"is_oa":true,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":"cc-by","license_id":"https://openalex.org/licenses/cc-by","version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Clin Pharmacol Drug Dev","raw_type":"Text"},{"id":"pmid:42925259","doi":null,"is_oa":false,"landing_page_url":"https://pubmed.ncbi.nlm.nih.gov/42925259","pdf_url":null,"source":{"id":"https://openalex.org/S4306525036","display_name":"PubMed","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Clinical pharmacology in drug development","raw_type":"Journal Article"}],"best_oa_location":{"id":"doi:10.1002/cpdd.70115","doi":"https://doi.org/10.1002/cpdd.70115","is_oa":true,"landing_page_url":"https://doi.org/10.1002/cpdd.70115","pdf_url":"https://onlinelibrary.wiley.com/doi/pdfdirect/10.1002/cpdd.70115","source":{"id":"https://openalex.org/S2764863641","display_name":"Clinical Pharmacology in Drug Development","issn_l":"2160-763X","issn":["2160-763X","2160-7648"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["cwts-core","dongbi-b","jufo-1","ki-jl-1","medline","norway-1","poland-40","russia-white-list-2"],"host_organization":"https://openalex.org/P4310320595","host_organization_name":"Wiley","host_organization_lineage":["https://openalex.org/P4310320595"],"host_organization_lineage_names":["Wiley"],"type":"journal"},"license":"cc-by","license_id":"https://openalex.org/licenses/cc-by","version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Clinical Pharmacology in Drug Development","raw_type":"journal-article"},"sustainable_development_goals":[{"id":"https://metadata.un.org/sdg/3","score":1.0,"display_name":"Good health and well-being"}],"study_designs":[{"id":"https://openalex.org/study-designs/randomized-controlled-trial","display_name":"Randomized Controlled Trial"},{"id":"https://openalex.org/study-designs/clinical-trial","display_name":"Clinical Trial"}],"awards":[],"funders":[{"id":"https://openalex.org/F4320306137","display_name":"Bill and Melinda Gates Foundation","ror":"https://ror.org/0456r8d26"},{"id":"https://openalex.org/F4320332736","display_name":"Novartis Pharma","ror":"https://ror.org/0013shd50"}],"has_content":{"grobid_xml":true,"pdf":true},"content_urls":{"pdf":"https://content.openalex.org/works/W7223474701.pdf","grobid_xml":"https://content.openalex.org/works/W7223474701.grobid-xml"},"referenced_works_count":17,"referenced_works":["https://openalex.org/W1606154210","https://openalex.org/W1988858173","https://openalex.org/W2769871898","https://openalex.org/W2898268232","https://openalex.org/W2903899730","https://openalex.org/W3007626557","https://openalex.org/W3008963226","https://openalex.org/W3015608194","https://openalex.org/W3080677494","https://openalex.org/W4210438208","https://openalex.org/W4212833497","https://openalex.org/W4225338642","https://openalex.org/W4308041525","https://openalex.org/W4318472692","https://openalex.org/W4391679133","https://openalex.org/W4402969550","https://openalex.org/W4416788354"],"related_works":["https://openalex.org/W7131297956","https://openalex.org/W4416788354","https://openalex.org/W7128501673","https://openalex.org/W4401236044","https://openalex.org/W7168030068","https://openalex.org/W3135540980","https://openalex.org/W4387219616","https://openalex.org/W3133559609","https://openalex.org/W4412363913","https://openalex.org/W4407223680"],"abstract_inverted_index":{"Abstract":[0],"Antiviral":[1],"therapy":[2],"is":[3,11],"needed":[4],"to":[5,82],"address":[6],"acute":[7],"coronavirus":[8,18,214],"disease.":[9,215],"EGT710":[10,34,89,91,130,171,195],"a":[12,47,60,211],"novel":[13],"low\u2010molecular\u2010weight":[14],"inhibitor":[15],"of":[16,33],"the":[17,28,42],"main":[19],"protease":[20],"(M":[21],"pro":[22],").":[23],"This":[24],"first\u2010in\u2010human":[25],"study":[26,39],"evaluated":[27],"safety,":[29],"tolerability,":[30],"and":[31,69,85,142,146,158,167,197,201],"pharmacokinetics":[32,205],"in":[35,41],"healthy":[36],"adults.":[37],"The":[38],"conducted":[40],"Netherlands":[43],"involved":[44],"three":[45],"parts:":[46],"blinded,":[48],"placebo\u2010controlled,":[49],"3:1":[50],"randomized,":[51,75],"single":[52],"ascending":[53,62],"dose":[54,63],"Part":[55,64,77],"A":[56],"(n":[57,66,79],"=":[58,67,80],"39);":[59],"multiple":[61],"B":[65],"31);":[68],"an":[70],"open\u2010label,":[71],"three\u2010period,":[72],"six":[73],"sequence,":[74],"cross\u2010over":[76],"C":[78,143,163],"18)":[81],"evaluate":[83],"food":[84],"formulation":[86],"effects":[87],"on":[88,187],"bioavailability.":[90],"was":[92,119,131,154,199],"well":[93,202],"tolerated.":[94],"All":[95],"adverse":[96,128],"events":[97],"(AEs)":[98],"were":[99],"mild":[100,111],"(Grade":[101],"1),":[102],"with":[103,115,123,150,204],"no":[104,124,147,185],"serious":[105],"AEs":[106,113],"or":[107,126],"discontinuations.":[108],"Aside":[109],"from":[110],"gastrointestinal":[112],"associated":[114],"EGT710,":[116],"AE":[117],"frequency":[118],"similar":[120],"between":[121,156],"groups":[122],"dose\u2010dependent":[125],"dose\u2010limiting":[127],"effects.":[129],"rapidly":[132],"absorbed":[133],"(median":[134],"T":[135],"max":[136,144,164],"2.0":[137],"h),":[138],"showed":[139],"sub\u2010proportional":[140],"AUC":[141,168],"increases":[145],"significant":[148],"accumulation":[149],"daily":[151,175],"dosing.":[152],"Bioavailability":[153],"comparable":[155],"suspension":[157],"capsule":[159],"formulations.":[160],"Food":[161],"increased":[162],"by":[165,169],"20%":[166],"27%.":[170],"700":[172],"mg":[173],"once":[174],"for":[176,213],"7":[177],"days":[178],"modestly":[179],"induced":[180],"CYP3A4":[181],"activity":[182],"but":[183],"had":[184],"effect":[186],"organic":[188],"anion":[189],"transporting":[190],"polypeptide":[191],"(OAT1/3)":[192],"activity.":[193],"Oral":[194],"(capsule":[196],"suspension)":[198],"safe":[200],"tolerated,":[203],"that":[206],"support":[207],"further":[208],"development":[209],"as":[210],"treatment":[212]},"counts_by_year":[],"updated_date":"2026-10-31T12:09:11.096373","created_date":"2026-10-25T00:00:00"}